Unii-950o97nupo
Unii-950o97nupo Basic information
- Product Name:
- Unii-950o97nupo
- Synonyms:
-
- 2-(2-Furanyl)-7-[2-[4-[4-(2-Methoxyethoxy)phenyl]-1-piperazinyl]ethyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyriMidin-5-aMine
- 2-Furan-2-yl-7-(2-{4-[4-(2-Methoxy-ethoxy)-phenyl]-piperazin-1-yl}-ethyl)-7,9a-dihydro-5H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyriMidin-5-ylaMine
- 7H-Pyrazolo(4,3-E)(1,2,4)triazolo(1,5-C)pyrimidin-5-amine, 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-
- Preladenant
- SCH-420814
- Unii-950o97nupo
- 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-ethyl)-7H-pyrazolo[4,3-e][1,2,4
- Sch 420814 Preladenant
- CAS:
- 377727-87-2
- MF:
- C25H29N9O3
- MW:
- 503.56
- Product Categories:
-
- Amines
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Mol File:
- 377727-87-2.mol
Unii-950o97nupo Chemical Properties
- Density
- 1.47±0.1 g/cm3(Predicted)
- storage temp.
- -20°
- solubility
- Soluble in DMSO (up to 5 mg/ml with warming).
- form
- solid
- pka
- 6.42±0.40(Predicted)
- color
- Beige
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
Unii-950o97nupo Usage And Synthesis
Description
Preladenant is an orally bioavailable antagonist of the adenosine A2A receptor (Kis = 1.1 and 2.5 nM for human and rat receptors, respectively). It is selective for A2A receptors over A1, A2B, and A3 receptors (Kis = >1,000, >1,700, and >1,000 nM, respectively) as well as a panel of 59 receptors, enzymes, and ion channels. Preladenant inhibits adenylate cyclase activity (Kbs = 1.3 and 0.7 nM for human and rat receptors, respectively) induced by the A2A receptor agonist CGS 21680 . It inhibits catalepsy induced by haloperidol in rats by 77 and 70% after 1 and 4 hours, respectively, when administered at a dose of 1 mg/kg. Preladenant also increases the efficacy of L-DOPA when used in combination with eltoprazine in a 6-OHDA rat lesion model of Parkinson’s disease dyskinesia.
Uses
A potent and selective antagonist at the adenosine A2A receptor. It is being researched as a potential treatment for Parkinson''s disease.
in vivo
Preladenant (1 mg/kg) inhibits L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias. Preladenant exhibits antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test[1]. Preladenant produces a dose-dependent reduction in parkinsonian scores at doses of 1 mg/kg (min score: 9.0) and 3 mg/kg (min score: 6.5). A subthreshold dose of Preladenant reduces minimum and mean parkinsonian scores in animals treated with 3 mg kg of L-Dopa to 5.25 and 6.88 respectively. A Wilcoxin test is used to compare individual treatments against vehicle. Preladenant (3 mg/kg), L-Dopa (3, 6, and 12 mg/kg), and the combination of Preladenant and L-Dopa (1 or 3 mg/kg+3 mg/kg) are all significantly improved on the minimum parkinsonian score. In addition, both the 12 mg/kg L-Dopa and L-Dopa+Preladenant groups are significantly improved on both minimum and mean parkinsonian scores relative to the 3 mg/kg L-Dopa group[2].
target
adenosine A2A receptor
References
[1] ROBERT A HODGSON. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression.[J]. Journal of Pharmacology and Experimental Therapeutics, 2009, 330 1: 294-303. DOI:10.1124/jpet.108.149617
[2] ROBERT A. HODGSON . Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders[J]. Experimental Neurology, 2010, 225 2: Pages 384-390. DOI:10.1016/j.expneurol.2010.07.011
[3] ANNALISA PINNA PHD, DVM. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson’s disease[J]. Movement Disorders, 2016, 31 4: 501-511. DOI:10.1002/mds.26475
[4] PAUL A BEAVIS. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110 36: 14711-14716. DOI:10.1073/pnas.1308209110
[5] STEPHEN M HATFIELD Michail S. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer[J]. Current Opinion in Pharmacology, 2016, 29: Pages 90-96. DOI:10.1016/j.coph.2016.06.009
[6] OHTA A. A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.[J]. Frontiers in Immunology, 2016: 109. DOI:10.3389/fimmu.2016.00109
[7] NCT03099161
Unii-950o97nupoSupplier
- Tel
- sales@boylechem.com
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 021-50795510 4000665055
- sales@accelachem.com
- Tel
- 17702719238 18971495150;
- sales@sun-shinechem.com
- Tel
- 021-50135380
- shchemsky@sina.com